^
    over1year
    A next-generation sequencing methylation assay for sub-typing small cell lung cancer in cell-free DNA. (ASCO 2023)
    We showed a cfDNA methylation profiling platform that could support disease sub-typing for SCLC. This platform has great potential in disease stratification and patient management.
    Next-generation sequencing • Epigenetic controller
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1) • POU2F3 (POU Class 2 Homeobox 3) • NEUROD1 (Neuronal Differentiation 1)
    |
    MYC amplification
    |
    Resolution ctDx FIRST Assay
    almost2years
    Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test (Agilent Technologies Press Release)
    "Agilent Technologies Inc....announced an agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services. The alliance will enable providers and patients throughout the United States to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test....The agreement between Quest and Agilent will enable broad adoption for ctDx FIRST, a single-site premarket approved (ssPMA) test performed at the Resolution Bioscience CLIA laboratory in Kirkland, Washington....Under the terms of the agreement, Quest will offer ctDx FIRST to healthcare providers in the United States seeking a minimally invasive liquid biopsy test option as a CDx for KRAZATI."
    Licensing / partnership
    |
    Resolution ctDx FIRST Assay
    |
    Krazati (adagrasib)
    almost2years
    Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer (Agilent Technologies Press Release)
    "Agilent Technologies...announced today that the U.S. Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). This is the first liquid biopsy NGS assay approved by the FDA as a CDx for the newly approved KRAZATI in advanced NSCLC and was developed in collaboration with Mirati Therapeutics."
    FDA event
    |
    Resolution ctDx FIRST Assay
    |
    Krazati (adagrasib)